Colorectal Cancer, Cholangiocarcinoma
Conditions
Keywords
Medtronic Pump, Codman Catheter, Hepatic Arterial Infusion (HAI), Floxuridine (FUDR), Gemcitabine, Oxaliplatin, Irinotecan (CPT-11), Fluorouracil, Leucovorin Calcium (Folinic Acid), Dexamethasone
Brief summary
This study is being done to answer the following question: Is the combination of the Medtronic pump and the Codman catheter device a safe alternative to the C3000 Codman pump for delivering chemotherapy directly into the liver of patients with metastatic colorectal cancer or cholangiocarcinoma?
Detailed description
Group 1 unresectable liver metastases from colorectal cancer \- Patients will receive either FOLFIRI, FOLFOX, Irinotecan or Irinotecan/oxaliplatin (anti- EGFR agent may be added to any of the systemic treatments) on Days 1 and 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement. Group 2 resectable liver metastases from colorectal cancer - Patients will receive either FOLFIRI, FOLFOX, Irinotecan or Irinotecan/oxaliplatin on Days 1 and 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement. Group 3 unresectable cholangiocarcinoma \- Patients will receive Gemcitabine (800 mg/m2 IV over 30 minutes) and Oxaliplatin (85 mg/ m2 IV over 120 minutes) or Gemcitabine (1000 mg/m2 IV over 30 minutes) alone on Days 1 and 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement.
Interventions
All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
Please see Detailed Description.
DRUGGemcitabine
Please see Detailed Description.
DRUGOxaliplatin
Please see Detailed Description.
Please see Detailed Description.
DRUGFluorouracil
Please see Detailed Description.
Please see Detailed Description.
Sponsors
Virginia Mason Hospital/Medical Center
Benaroya Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Pilot non- randomized safety study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinically or radiographically confirmed extrahepatic disease (or) Histologically confirmed cholangiocarcinoma (Clinical or radiographic evidence of metastatic disease that has been resected is allowed, provided there is no recurrence in that area prior to protocol consent) 2. Confirmation of diagnosis must be performed at VMMC 3. Participant may have completely resected hepatic metastases without current evidence of other metastatic disease 4. Lab values ≤14 days prior to registration: ANC ≥ 1.0(9)/L Platelet count ≥ 75 (9)/L Creatinine ≤1.8 mg/dL AST 0 to 2x reference value ALK PHOS 0 to \< 1.2 x reference value Tot Bili 0 to \< 1.2 x reference value 5. Prior chemotherapy is acceptable if last dose of oxaliplatin or irinotecan is given ≥3 weeks prior to planned first dosing on this protocol. 5-FU or 5-FU leucovorin may be given ≥2 weeks prior to planned first dosing on this protocol. \[Note: no chemotherapy to be given after resection of liver lesions prior to treatment on this study\] 6. Any investigation agent is acceptable if administered ≥3 months before planned first dose on this protocol 7. ECOG \<=1 8. Participants ≥18 years of age
Exclusion criteria
1. Prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if competed at least 4 weeks prior to the planned first dose of treatment on protocol) 2. Colorectal cancer that is BRAF mutant or defective in mismatch repair. 3. Active infection, ascites, hepatic encephalopathy 4. Female participants who are pregnant or lactating - or planning to become pregnant within 6 months after the end of the treatment (female participants of child-bearing potential must have negative pregnancy test ≤72 hours before treatment start) 5. If in the opinion of the treating investigator a participant has any serious medical problems which may preclude receiving this type of treatment 6. Participants with current evidence of hepatitis A, B, C (i.e., active hepatitis) 7. Participants with history or known presence of primary CNS tumors, seizures not well- controlled with standard medical therapy, or history of stroke will also be excluded 8. Serious or non-healing active wound, ulcer, or bone fracture 9. History of other malignancy, except: 1. Malignancy treated with curative intent and with no known active disease present for ≥3 years prior to registration and felt to be at low risk for recurrence by the treating physician 2. Adequately treated non-melanomatous skin cancer or lentigo malignant without evidence of disease 3. Adequately treated cervical carcinoma in situ without evidence of disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients requiring stent replacements | 1 year | — |
| Percent frequency liver toxicity | 1 year | Alkaline phosphatase percent toxicity, Serum bilirubin percent toxicity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 1 year | Overall survival is defined as the time from treatment initiation till the day of death or last follow-up whichever occurs first. |
| Progression free survival | 1 year | Progression free survival is defined as the time from treatment initiation till the day of progression or death whichever occurs first. Patients that are alive without progression at the end of the study will be censored. |
Countries
United States
Contacts
Primary ContactHagen Kennecke, MD
Outcome results
None listed